Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $92.79 Average PT from Brokerages
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) have earned an average rating of “Moderate Buy” from the fourteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target […]
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) have earned an average rating of “Moderate Buy” from the fourteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target […]
